 |
 |
 |
|
 |
|
Jeffrey Wolf
CEO
Lynn Whittington
Chief Technology Officer
Kenneth R.
Weisshaar
Chief Strategic Officer
Ari Reubin
Vice President of Business Development
Steve Scott
Vice President of Development
Paul Belsky, M.D.
Vice President of Medical Affairs
|
Board
of Directors
Ronald G. Gelbman
Director
Ronald A. Matricaria
Director
Richard D. Palmer, Ph.D.
Director
Frank Young, M.D., Ph.D.
Director
Jeff Himawan, Ph.D.
Director
|
Scientific
Advisory Board
Sundaresan Jayaraman
Chairman
Mitchell P. Fink, M.D.
Maria I. New, M.D.
John G. Webster, Ph.D
Frank Young, M.D., Ph.D.
Jeff Himawan, Ph.D.
|
|
|
|
Jeffrey
Wolf
CEO
Mr. Wolf has substantial experience in
creating, financing, nurturing and growing
new ventures based upon breakthrough research
and technology. Mr. Wolf was previously the
Managing General Partner of Seed-One Ventures,
LLC, a New York based venture capital firm,
where he founded and served as CEO and Chairman
of several start-up companies including EluSys
Therapeutics, Inc., a venture-backed biotechnology
company. Mr. Wolf received his MBA from Stanford
Business School, his JD from New York University
School of Law and his BA from the University
of Chicago.
|
|
|
Lynn
Whittington
Chief Technology Officer
Lynn Whittington brings more than 30 years
of experience in information sciences, computer
architecture and development of wireless communications
systems to his role as Chief Technology Officer
of Sensatex, Inc. In this position, he will
focus on defining, designing and integrating
the technology requirements for a highly reliable
system of real-time acquisition, processing,
transmission, management and presentation
of critical data. Prior to Sensatex, Mr. Whittington
spent more than 20 years with Motorola, most
recently as the Chief Technologist for the
company's next generation wireless network,
Aspira, where he co-led the 275-person Network
Architecture & Technology organization.
During that time, he was heavily involved
in the convergence of wireless and Internet
technologies, addressing issues of high system
reliability between those environments. Before
joining Motorola, he spent 10 years as a systems
engineer with Unitech in Austin, TX, where
he focused on communications, graphics and
mass storage technologies. Mr. Whittington
holds five patents from the U.S. Patent office
in the area of communications, semiconductors
and computers, and is the author of numerous
papers and presentations at major industry
conferences such as SuperComm and the International
Engineering Consortium. He received a BSEE
in Information Science and MSEE in Computer
Architecture from the University of Texas
at Austin.
|
|
|
Kenneth
R. Weisshaar
Chief Strategic Officer
Mr. Weisshaar has 26 years of experience
in the executive and managerial leadership
of global technology-based businesses. Prior
to joining Sensatex, he served as Chief Financial
Officer of Becton Dickinson, a $3.4 billion
global medical devices and biosciences corporation.
During his 11-year term there, he also served
as President of the Worldwide Consumer Healthcare
business, President of the Bioscience Cell
Analysis Sector, President of the global medical
supplies business, and Vice President of Corporate
Planning and Development. Prior to Becton
Dickinson, Mr. Weisshaar was a Senior Engagement
Manager at McKinsey & Company, where he consulted
with top management of healthcare and manufacturing
industries on issues of business strategy,
operations, marketing and product development.
Prior to McKinsey, he served in various managerial
roles at Raychem Corporation, a high technology
manufacturer of the electronics, telecom,
and energy industries. Mr. Weisshaar received
his BS in Chemical Engineering from the Massachusetts
Institute of Technology and his MBA from Harvard
Business School.
|
|
|
Ari
Reubin
Vice President of Business Development
Ari Reubin brings 15 years of experience in
strategic marketing, alliances, capital markets,
product management, operations, and engineering
within the semiconductor, telecommunications,
and notebook computer industries. He spent
over 10 years at Texas Instruments, where
he served as Director of the worldwide Digital
Image Sensor Products group, Director of Strategic
Alliances for the Notebook Computer group,
Manager of Technology Transfer for TI at the
Sematech consortium, and in key engineering
positions. Mr. Reubin has also served as an
Adjunct Professor at the University of Texas
at Dallas Business School. In 1998, he co-founded
Darwin‚ s Beagle, a venture consulting
firm. He holds a BS in Materials Engineering
and Marketing Management from Michigan State
University and an MS in Polymer Engineeringfrom
the University of Illinois at Urbana-Champaign.
|
|
Steve
Scott
Vice President of Development
Steve Scott brings almost 20 years of experience
in software development, hardware development,
computer architecture and development of wireless
communications systems to Sensatex. In this
position, he will focus on architecting, developing,
and delivering a highly reliable system for
real-time acquisition, processing, transmission,
management and presentation of critical data.
Prior to Sensatex, Mr. Scott spent more than
18 years with Motorola, most recently as a
major software architect for the company's
next generation wireless network, Aspira.
During that time, he was a major contributor
in the convergence of wireless and Internet
technologies, focusing on the development
of highly extensible and reliable wireless
access-independent core networks. Mr. Scott
received a BSEE from Wichita State University
and an MSEE from the University of Texas at
Arlington.
|
|
Paul
Belsky, M.D.
Vice President of Medical Affairs
Dr. Belsky has expertise in the clinical practice
of internal medicine and cardiovascular diseases.
Prior to his training in cardiology, Dr. Belsky
was on the clinical academic faculty at Cornell
Medical College and was a member of the Cornell
Medical Practice. He is a fellow of the American
College of Cardiology, the American College
of Chest Physicians, a member of the American
College of Physicians and a Clinical Assistant
Professor of Medicine at New York University
School of Medicine. He was formerly a Vice
President at Athena Ventures, LLC. Dr. Belsky
received his M.D. from the University of California
at San Francisco, and his A.B. in Biology
from Brown University, where he was elected
Phi Beta Kappa.
|
|
Board of Directors
|
|
Ronald
G. Gelbman
Director
Mr. Gelbman is a former member of the Executive
Committee of Johnson & Johnson. In 1998,
he was named Worldwide Chairman of the Health
Systems and Diagnostics Group, becoming responsible
for Johnson & Johnson businesses such
as Healthcare Systems, Lifescan, Ortho-Clinical
Diagnostics, and Therakos. In addition, Mr.
Gelbman was responsible for guiding Johnson
& Johnson's annual strategic planning
process and led the Reengineering Task Force.
Previous to this, Mr. Gelbman served as Worldwide
Chairman of Johnson & Johnson's Pharmaceuticals
and Diagnostics Group, a position to
which he was appointed in 1994. In his 27
years at Johnson & Johnson, Mr. Gelbman
also served as the Group Chairman of Janssen
GmbH, the Vice President of Johnson &
Johnson International, and various other managerial
positions. He received his BA from Rollins
College and his MBA from the Crummer School
of Business.
|
|
Ronald
A. Matricaria
Director
Ronald Matricaria currently serves as Chairman
of the board of directors of St. Jude Medical,
Inc., the undisputed global leader of heart
valve products and a major supplier of cardiac
rhythm management products and services. Until
1999, he also served as President and CEO
of St. Jude. In his six years with the Company,
Mr. Matricaria led its diversification from
one to three technology platforms, and oversaw
a revenue increase from $225MM to over $1.1
billion and an employee base expansion from
700 to 5,000. Prior to St. Jude Medical, Mr.
Matricaria spent 23 years with Eli Lilly and
Company, Inc., where he held various executive-level
positions such as EVP of the Pharmaceutical
Division, President of North American operations,
and President of Eli Lilly International Corporation.
Mr. Matricaria received his BS degree from
the Massachusetts College of Pharmacy and
was also awarded an honorary Doctor of Science
degree in pharmacy in recognition of his contributions
to the practice of pharmacy.
|
|
Richard
D. Palmer, Ph.D.
Director
Richard (David) Palmer, a founding investor
in Sensatex Inc., has been a first-round investor
in several successful health-care related
start-ups. From 1972 until 1993, he founded
several privately-held real estate development
companies and other service businesses. Dr.
Palmer is currently president of Palm Florida
Management, a group that manages various real
estate and investment assets. For over 20
years, he taught Management Ethics at SUNY
College at Fredonia, New York. He received
his BA and MA from Oberlin College and his
Ph.D. in Philosophy from Ohio State University.
|
|
Jeff
Himawan, Ph.D.
Director
Dr. Himawan has extensive experience in guiding
and managing the research and development
of scientific enterprises with commercial
objectives. Prior to Sensatex, Dr. Himawan
co-founded and served as Chief Scientific
Officer at EluSys Therapeutics, a venture-backed
biotechnology company. Prior to EluSys, Dr.
Himawan was Managing Director at Athena Ventures,
LLC. Before his time at Athena, Dr. Himawan
was employed at Genzyme Corporation, a biotechnology
company located in Cambridge, Massachusetts.
He is a member of the New York Academy of
Sciences, Sigma Xi (The Scientific Research
Society), the American Society for Microbiology,
and the American Association for the Advancement
of Science. Dr. Himawan holds a Ph.D. degree
from the Department of Biological Chemistry
and Molecular Pharmacology at Harvard University
and a BS in Life Sciences from the Massachusetts
Institute of Technology.
send
email
|
|
Frank
Young, M.D., Ph.D.
Director
Dr. Young has an extensive background in immunology,
regulatory and defense-related affairs. He
currently serves on the Board of Directors
for EluSys Therapeutics. Dr. Young was formerly
Commissioner of the FDA. Dr. Young's other
public service work includes positions as
a Rear Admiral at the U.S. Public Health Service
and a senior advisor to DARPA. Dr. Young is
also a member of the National Academy of Sciences.
Dr. Young received his BA from Union College,
his M.D. from the University of the State
of New York and his Ph.D. from Western Reserve
University.
|
|
Scientific Advisory Board
|
|
Sundaresan
Jayaraman
Chairman
Dr. Jayaraman is the primary developer of
the Smart Shirt Wearable Motherboard!".
He currently serves as a Professor of Textile
Engineering at the Georgia Institute of Technology,
where he has been since 1985. Dr. Jayaraman
received the 1989 Presidential Young Investigator
Award from the National Science Foundation
for his research in the area of computer aided
manufacturing and enterprise architecture.
In 1994, he was elected a fellow of the Textile
Institute (UK) and in 1997, received the Georgia
Outstanding Manufacturing Researcher of the
Year Award from Georgians for Manufacturing.
Dr. Jayaraman's publications include a 1991
textbook on computer-aided problem solving
published by McGraw-Hill. He is also Technical
Editor of Information Technology for America's
Textiles International, a leading textile
trade publication, as well as an Editor for
the Journal of the Textile Institute, UK.
He received his Ph.D. from North Carolina
State University and his Masters and Bachelors
of Technology degrees from the University
of Madras in India.
|
|
Mitchell
P. Fink, M.D.
Dr. Fink is currently the Watson Professor
of Surgery, Anesthesiology, and Critical Care
Medicine, as well as Chief of the Division
of Critical Care Medicine at the University
of Pittsburgh Medical School and the University
of Pittsburgh Medical Center. Prior to this,
he was on the faculty of Harvard Medical School,
during which time he was named Johnson &
Johnson Professor of Surgery and Surgeon-in-Chief
at the Beth Israel Hospital. In 1986, while
serving on the faculty at the University of
Massachusetts Medical Center in Worcester
as a general/trauma surgeon and Director of
the Surgical Intensive Care Unit (SICU), Dr.
Fink received his first grant from the NIH
for research into the pathophysiology of sepsis
and septic shock. This topic has remained
the focus of his research interests for the
past twenty years and he has been continuously
funded by the NIH ever since. Dr. Fink has
won numerous awards for teaching and was honored
by the Society of Critical Care Medicine with
the Laerdal Award and as a Millennium Speaker.
He has edited or co-edited eight books, all
dealing with various aspects of critical care
medicine. Dr. Fink obtained his M.D. degree,
graduating cum laude, from Washington University
School of Medicine in St. Louis and completed
his residency in General Surgery at the National
Naval Medical Center in Bethesda.
|
|
Maria I.
New, M.D.
Dr. New is Chairman of the Department of Pediatrics,
Pediatrician-in-Chief and Harold and Percy
Uris Professor of Pediatric Endocrinology
at the New York Hospital-Cornell Medical Center.
Dr. New's research is focused on the areas
of pediatric endocrinology, where she is known
for her pioneering research and clinical work
on congenital adrenal hyperplasia. Dr. New
and has received many honors and awards including
the Basic Science Award from the Society for
the Advancement of Women's Health Research
and the British Endocrine Society for Endocrinology
Dale Medal. Dr. New is also a member of numerous
professional and medical organizations and
was recently appointed to the National Advisory
Research Resources Council of the National
Institutes of Health. She has served as a
member of the Food and Drug Administration's
Endocrine and Metabolic Drug Advisory Committee
since 1994 and was recently elected to the
National Academy of Sciences. Dr. New received
her BA at Cornell University and her M.D.
from the University of Pennsylvania.
|
|
John
G. Webster, Ph.D.
Dr. Webster is a Professor of Biomedical Engineering
at the University of Wisconsin-Madison. His
professional research areas include medical
instrumentation and sensors, electrode design,
sensors for vigilance and alertness, measuring
ventilation and apnea, monitoring and stimulating
electrodes, biopotential amplifiers and interference,
design of cardiac pacemakers and defribrillators,
and the design of pulse oximeters. Dr. Webster
has consulted for a large number of medical
device manufacturers, including 3M, General
Electric, and Healthdyne. He is editor of
the most-used text in biomedical engineering,
Medical Instrumentation: Application and Design,
Third Edition, and has developed 18 other
books, including the Encyclopedia of Medical
Devices and Instrumentation. Dr. Webster is
a Fellow of the Institute of Electrical and
Electronics Engineers, Instrument Society
of America, American Institute of Medical
and Biological Engineering, and Institute
of Physics. He is the recipient of the AAMI
Foundation Laufman-Greatbatch Prize and the
ASEE/Biomedical Engineering Division, Theo
C. Pilkington Outstanding Educator Award.
He has also been a member of the IEEE-EMBS
Administrative Committee and the NIH Surgery
and Bioengineering Study Section. He received
his BEE from Cornell University and his MSEE
and Ph.D. from the University of Rochester.
|
|
|
Jeff
Himawan, Ph.D.
Dr. Himawan has extensive experience in
guiding and managing the research and development
of scientific enterprises with commercial
objectives. Prior to Sensatex, Dr. Himawan
co-founded and served as Chief Scientific
Officer at EluSys Therapeutics, a venture-backed
biotechnology company. Prior to EluSys, Dr.
Himawan was Managing Director at Athena Ventures,
LLC. Before his time at Athena, Dr. Himawan
was employed at Genzyme Corporation, a biotechnology
company located in Cambridge, Massachusetts.
He is a member of the New York Academy of
Sciences, Sigma Xi (The Scientific Research
Society), the American Society for Microbiology,
and the American Association for the Advancement
of Science. Dr. Himawan holds a Ph.D. degree
from the Department of Biological Chemistry
and Molecular Pharmacology at Harvard University
and a BS in Life Sciences from the Massachusetts
Institute of Technology.
|
|
Frank
Young, M.D., Ph.D.
Dr. Young has an extensive background in immunology,
regulatory and defense-related affairs. He
currently serves on the Board of Directors
for EluSys Therapeutics. Dr. Young was formerly
Commissioner of the FDA. Dr. Young's other
public service work includes
positions as a Rear Admiral at the U.S. Public
Health Service and a senior advisor to DARPA.
Dr. Young is also a member of the National
Academy of Sciences. Dr. Young received his
BA from Union College, his M.D. from the University
of the State of New York and his Ph.D. from
Western Reserve University.
top
|
|
|
|
|
|
|
|
